Klacid Sr

Clarithromycin, the active ingredient in Klacid Sr, is a macrolide antibiotic presented as an oral tablet for systemic use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, skin and soft‑tissue infections, and is part of combination therapy for Helicobacter pylori eradication, and is commonly prescribed in adult patients.

GNH USA supplies Klacid Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, health‑care institutions and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections in the respiratory, sinus and skin pathways. - Community‑acquired pneumonia: reduces bacterial load and improves clinical symptoms in adult patients. - Acute bacterial sinusitis: alleviates sinus inflammation and clears infection. - Skin and soft‑tissue infections: eradicates susceptible Gram‑positive and some Gram‑negative organisms. - Helicobacter pylori eradication: used in combination regimens to achieve bacterial clearance and prevent ulcer recurrence.

Clarithromycin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often self‑limiting. - Abdominal pain: cramping or discomfort. - Taste disturbance: metallic or altered taste perception. - Headache: mild to moderate intensity. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - QT interval prolongation: risk of cardiac arrhythmias. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe allergic reactions: anaphylaxis, rash, or angioedema. - Cardiac arrhythmias: especially in patients with pre‑existing heart disease. - Liver failure: rare but potentially life‑threatening.

Before prescribing clarithromycin, clinicians should evaluate patient‑specific factors and monitor for adverse events. - Assess renal function: dose adjustment may be needed in renal impairment. - Monitor liver enzymes: avoid use in patients with active hepatic disease. - Review concomitant QT‑prolonging drugs: increased risk of arrhythmia. - Use with caution in patients with cardiac disease: monitor ECG if indicated. - Avoid in individuals with known hypersensitivity to macrolides. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Clarithromycin interacts with several medications; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Co‑administration with other QT‑prolonging agents (e.g., erythromycin, cisapride) may cause serious arrhythmias. - Strong CYP3A4 substrates (e.g., simvastatin, lovastatin) can lead to toxic levels. - Antacids containing aluminum or magnesium: reduce clarithromycin absorption.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - Carbamazepine: may decrease clarithromycin plasma concentrations. - Oral contraceptives: reduced efficacy, consider alternative contraception.